KIR-HLA intercourse in HIV disease

Trends in Microbiology

Volumn 16, Issue 12, 2008, Pages 620-627

  Carrington, Mary ^a   Martin, Maureen P ^a   van Bergen, Jeroen ^b  

^a SAIC FREDERICK INC   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

CELL ACTIVITY; DISEASE COURSE; GENE ACTIVATION; GENE ACTIVITY; GENE CLUSTER; GENE EXPRESSION; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INNATE IMMUNITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VIRUS LOAD; VIRUS RESISTANCE;

DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HLA ANTIGENS; HLA-B ANTIGENS; HUMANS; KILLER CELLS, NATURAL; RECEPTORS, KIR; RECEPTORS, KIR3DL1; RECEPTORS, KIR3DS1;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 56649106462     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2008.09.002     Document Type: Review

References (81)

1. Dean M., et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273 (1996) 1856-1862
2. Liu R., et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86 (1996) 367-377
3. Martin M.P., et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282 (1998) 1907-1911
4. McDermott D.H., et al. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 352 (1998) 866-870
5. Samson M., et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382 (1996) 722-725
6. Zimmerman P.A., et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol. Med. 3 (1997) 23-36
7. Gonzalez E., et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307 (2005) 1434-1440
8. Liu H., et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 4581-4585
9. Fellay J., et al. A whole-genome association study of major determinants for host control of HIV-1. Science 317 (2007) 944-947
10. Lanier L.L. NK cell recognition. Annu. Rev. Immunol. 23 (2005) 225-274
11. Bancroft G.J. The role of natural killer cells in innate resistance to infection. Curr. Opin. Immunol. 5 (1993) 503-510
12. Biron C.A., and Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr. Opin. Immunol. 13 (2001) 458-464
13. Robertson M.J., and Ritz J. Biology and clinical relevance of human natural killer cells. Blood 76 (1990) 2421-2438
14. Trinchieri G. Biology of natural killer cells. Adv. Immunol. 47 (1989) 187-376
15. Storkus W.J., et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 2361-2364
16. Hoglund P., et al. Recognition of beta 2-microglobulin-negative (beta 2m-) T-cell blasts by natural killer cells from normal but not from beta 2m- mice: nonresponsiveness controlled by beta 2m- bone marrow in chimeric mice. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 10332-10336
17. Karre K., et al. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319 (1986) 675-678
18. Wiertz E., et al. Cytomegaloviruses use multiple mechanisms to elude the host immune response. Immunol. Lett. 57 (1997) 213-216
19. Ljunggren H.G., and Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol. Today 11 (1990) 237-244
20. Voigt S., et al. Cytomegalovirus evasion of innate immunity by subversion of the NKR-P1B:Clr-b missing-self axis. Immunity 26 (2007) 617-627
21. Guerra N., et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28 (2008) 571-580
22. Diefenbach A., and Raulet D.H. Strategies for target cell recognition by natural killer cells. Immunol. Rev. 181 (2001) 170-184
23. Arase H., et al. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 296 (2002) 1323-1326
24. Smith H.R., et al. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 8826-8831
25. Biassoni R., et al. Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur. J. Immunol. 27 (1997) 3095-3099
26. Chewning J.H., et al. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J. Immunol. 179 (2007) 854-868
27. Foley B., et al. KIR2DS1-mediated activation overrides NKG2A-mediated inhibition in HLA-C C2-negative individuals. Int. Immunol. 20 (2008) 555-563
28. George T.C., et al. Tolerance and alloreactivity of the Ly49D subset of murine NK cells. J. Immunol. 163 (1999) 1859-1867
29. Stewart C.A., et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 13224-13229
30. Desrosiers M.P., et al. Epistasis between mouse Klra and major histocompatibility complex class I loci is associated with a new mechanism of natural killer cell-mediated innate resistance to cytomegalovirus infection. Nat. Genet. 37 (2005) 593-599
31. Anderson S.K., et al. The ever-expanding Ly49 gene family: repertoire and signaling. Immunol. Rev. 181 (2001) 79-89
32. Kulkarni, S. et al. (2008) The Yin and Yang of HLA and KIR in human disease. Semin. Immunol. 10.1016/j.smim.2008.06.003
33. Cella M., et al. NK3-specific natural killer cells are selectively inhibited by Bw4- positive HLA alleles with isoleucine 80. J. Exp. Med. 180 (1994) 1235-1242
34. Gumperz J.E., et al. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J. Exp. Med. 181 (1995) 1133-1144
35. Muller C.A., et al. Genetic and serological heterogeneity of the supertypic HLA-B locus specificities Bw4 and Bw6. Immunogenetics 30 (1989) 200-207
36. Carr W.H., et al. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J. Immunol. 175 (2005) 5222-5229
37. Gumperz J.E., et al. Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell- inhibitory receptor. J. Immunol. 158 (1997) 5237-5241
38. Luque I., et al. Threonine 80 on HLA-B27 confers protection against lysis by a group of natural killer clones. Eur. J. Immunol. 26 (1996) 1974-1977
39. Martin M.P., et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39 (2007) 733-740
40. Gao X., et al. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat. Med. 11 (2005) 1290-1292
41. Goulder P.J., et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3 (1997) 212-217
42. Phillips R.E., et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354 (1991) 453-459
43. Carr W.H., et al. Cutting Edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation. J. Immunol. 178 (2007) 647-651
44. O'Connor G.M., et al. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J. Immunol. 178 (2007) 235-241
45. Pascal V., et al. Detection of KIR3DS1 on the cell surface of peripheral blood NK cells facilitates identification of a novel null allele and assessment of KIR3DS1 expression during HIV-1 infection. J. Immunol. 179 (2007) 1625-1633
46. Trundley A., et al. Allelic expression patterns of KIR3DS1 and 3DL1 using the Z27 and DX9 antibodies. Eur. J. Immunol. 37 (2007) 780-787
47. Alter G., et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J. Exp. Med. 204 (2007) 3027-3036
48. Valiante N.M., et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7 (1997) 739-751
49. Johansson S., et al. Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules. J. Exp. Med. 201 (2005) 1145-1155
50. Shilling H.G., et al. Genetic control of human NK cell repertoire. J. Immunol. 169 (2002) 239-247
51. Yawata M., et al. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J. Exp. Med. 203 (2006) 633-645
52. Anfossi N., et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 25 (2006) 331-342
53. Fernandez N.C., et al. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 105 (2005) 4416-4423
54. Kim S., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436 (2005) 709-713
55. Kim S., et al. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 3053-3058
56. Martin M.P., et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31 (2002) 429-434
57. Qi Y., et al. KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog. 2 (2006) e79
58. Gaudieri S., et al. Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes Immun. 6 (2005) 683-690
59. Barbour J.D., et al. Synergy or independence? Deciphering the interaction of HLA Class I and NK cell KIR alleles in early HIV-1 disease progression. PLoS Pathog. 3 (2007) e43
60. Long B.R., et al. Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J. Virol. 82 (2008) 4785-4792
61. Gardiner C.M., et al. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J. Immunol. 166 (2001) 2992-3001
62. Thomas R., et al. Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation?. J. Immunol. 180 (2008) 6743-6750
63. Rajagopalan S., et al. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol. 4 (2006) e9
64. Hoglund P., et al. Host MHC class I gene control of NK-cell specificity in the mouse. Immunol. Rev. 155 (1997) 11-28
65. Raulet D.H., et al. Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I-specific Ly49 receptors. Immunol. Rev. 155 (1997) 41-52
66. Scott-Algara D., et al. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J. Immunol. 171 (2003) 5663-5667
67. Boulet S., et al. Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS 22 (2008) 595-599
68. Boulet S., et al. A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. AIDS 22 (2008) 1487-1491
69. Ahlenstiel G., et al. Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. J. Clin. Invest. 118 (2008) 1017-1026
70. Ravet S., et al. Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood 109 (2007) 4296-4305
71. Carrington M., et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283 (1999) 1748-1752
72. Tang J., et al. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 15 (1999) 317-324
73. Gao X., et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N. Engl. J. Med. 344 (2001) 1668-1675
74. Flores-Villanueva P.O., et al. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5140-5145
75. Kaslow R.A., et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2 (1996) 405-411
76. Migueles S.A., et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 2709-2714
77. Just J.J. Genetic predisposition to HIV-1 infection and acquired immune deficiency virus syndrome: a review of the literature examining associations with HLA. Hum. Immunol. 44 (1995) 156-169
78. Lajoie J., et al. Genetic variants in nonclassical major histocompatibility complex class I human leukocyte antigen (HLA)-E and HLA-G molecules are associated with susceptibility to heterosexual acquisition of HIV-1. J. Infect. Dis. 193 (2006) 298-301
79. Matte C., et al. Functionally active HLA-G polymorphisms are associated with the risk of heterosexual HIV-1 infection in African women. AIDS 18 (2004) 427-431
80. Lopez-Vazquez A., et al. Interaction between KIR3DL1 and HLA-B*57 supertype alleles influences the progression of HIV-1 infection in a Zambian population. Hum. Immunol. 66 (2005) 285-289
81. Jennes W., et al. Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J. Immunol. 177 (2006) 6588-6592